Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NON INVASIVE MONITORING SYSTEMS INC /FL/NIMU · Entity 7976 | Director | September 03, 2025 | September 03, 2025 |
| OPKO HEALTH, INC.OPK · Entity 4891 | Sr. Vice President, CFO | July 24, 2026 | July 28, 2026 |
| VBI Vaccines Inc/BCVBIV · Entity 111039 | Director | June 14, 2018 | June 18, 2018 |
| Xenetic Biosciences, Inc.XBIO · Entity 8008 | Director | December 06, 2023 | December 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NON INVASIVE MONITORING SYSTEMS INC /FL/
Report date September 03, 2025 · Filed September 03, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2025-09-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
OPKO HEALTH, INC.
Report date July 24, 2026 · Filed July 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 563,396 |
Reported balance
After 2026-07-24 transaction · row 1
1 source rowRow 1 · 2026-07-24 · Tax withholding · Disposed 53,266 · Balance 563,396 F1: This number represents shares of common stock par value $0.01 per shares of OPKO Health, Inc. withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: This number represents shares of common stock par value $0.01 per shares of OPKO Health, Inc. withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units.
VBI Vaccines Inc/BC
Report date June 14, 2018 · Filed June 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares, no par value per shareSEC Table I · non-derivative | Direct | 37,500 |
Reported balance
After 2018-06-14 transaction · row 1
1 source rowRow 1 · 2018-06-14 · Exercise / conversion · Acquired 12,500 · Balance 37,500 F1: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. |
| Restricted Stock Units (RSUs)SEC Table II · derivative / convertible security | Direct | 12,500 |
Reported balance
After 2018-06-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-14 · Exercise / conversion · Disposed 12,500 · Balance 12,500 F1: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F2: The restricted stock units vest 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date.
F2: The restricted stock units vest 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date.
Xenetic Biosciences, Inc.
Report date December 06, 2023 · Filed December 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.29 · Expires 2033-12-06 | Direct | 2,500 |
Reported balance
After 2023-12-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-06 · Grant · Acquired 2,500 · Balance 2,500 F1: The Options vest 100% on the twelve-month anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Options vest 100% on the twelve-month anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 24, 2026 Filed Jul 28, 2026 20:24 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Tax withholdingCommon Stock | 53,266 | $1.22 | $64,984.52 |
DisclosureSEC source: 0001193125-26-321055 · ownership.xml · nonDerivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 563,396 F1 · shares: This number represents shares of common stock par value $0.01 per shares of OPKO Health, Inc. withheld to satisfy the tax withholding obligation due upon vesting of restricted stock units. Read SEC document |
| May 27, 2025 Filed May 29, 2025 21:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 437,500 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0000950170-25-079109 · ownership.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,500 Underlying: Common Stock · 437,500 shares Expires 2035-05-26 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 27, 2026. Read SEC document |
| July 24, 2024 Filed Jul 26, 2024 23:15 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantCommon Stock | 437,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-087036 · ownership.xml · nonDerivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 616,662 F1 · security: Each restricted stock unit represents a contingent right to receive one share of OPKO common stock upon the vesting of the award. The restricted stock units vest 50% on the second anniversary of the grant date, then 25% on each of the following two years. Read SEC document |
| December 06, 2023 Filed Dec 8, 2023 22:30 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 2,500 | $0.00 Strike: $4.29 | $0.00 |
DisclosureSEC source: 0001683168-23-008735 · ownership.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2033-12-06 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:36 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 700,000 | $0.00 Strike: $1.58 | $0.00 |
DisclosureSEC source: 0001209191-23-031032 · doc4.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 18, 2024. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 22:04 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001683168-22-008324 · ownership.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-12-07 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| December 07, 2021 Filed Dec 10, 2021 01:09 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001683168-21-006234 · ownership.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-12-07 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 21:11 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $4.81 | $0.00 |
DisclosureSEC source: 0001209191-21-012672 · doc4.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2031-02-18 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning February 19, 2022. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 22:04 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001683168-20-004206 · ownership.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-12-04 F1 · derivative.exercise_date: The Options vest 100% on the twelve-month anniversary of the grant date. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:13 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001209191-20-034957 · doc4.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2030-06-03 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning June 4, 2021. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 23:39 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001683168-19-003921 · ownership.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-12-04 F1 · derivative.exercise_date: The Options vest 100% on the twelve month anniversary of the grant date. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:03 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $2.47 | $0.00 |
DisclosureSEC source: 0001209191-19-040728 · doc4.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-06-30 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning July 1, 2020. Read SEC document |
| May 09, 2019 Filed May 10, 2019 10:13 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 3,150 | $2.04 | $6,426.00 |
DisclosureSEC source: 0001209191-19-028668 · doc4.xml · nonDerivative · entry 2 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,162 Read SEC document |
| May 09, 2019 Filed May 10, 2019 10:13 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 100 | $2.04 | $203.50 |
DisclosureSEC source: 0001209191-19-028668 · doc4.xml · nonDerivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,012 Read SEC document |
| November 28, 2018 Filed Nov 30, 2018 22:23 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 25,000 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001662252-18-000105 · ownership.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-11-28 F1 · derivative.exercise_date: The Options vest in equal quarterly installments over the twelve-month period commencing on the grant date. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:13 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001209191-18-039173 · doc4.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-06-20 F1 · derivative.exercise_date: The options were granted on June 21, 2018 and vest annually in four equal installments beginning on June 21, 2019. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 10:49 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-008818 · form4.xml · derivative · entry 2 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Shares · 12,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F2 · derivative.exercise_date: The restricted stock units vest 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date. F2 · derivative.expiration_date: The restricted stock units vest 1/3 per year annually over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 10:49 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | Exercise / conversionCommon Shares, no par value per share | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-18-008818 · form4.xml · nonDerivative · entry 1 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 22:05 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Exercise / conversionStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001209191-18-037294 · doc4.xml · derivative · entry 3 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2018-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options were granted on June 9, 2011 and vest in four equal installments beginning on June 9, 2012. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 22:05 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Tax withholdingCommon Stock | 63,946 | $4.26 | $272,409.96 |
DisclosureSEC source: 0001209191-18-037294 · doc4.xml · nonDerivative · entry 2 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,912 F1 · shares: Represents the number of shares withheld by the Company at the direction of the reporting person for payment of the exercise price and tax liability in connection with the exercise of the stock option. No shares of Common stock were sold by the reporting person in connection with this transaction. The reporting person has retained the net number of shares issued upon the exercise of the option, less the amount retained to pay the associated tax liability (11,054 of shares). F2 · price: Closing market price of the Company's common stock on the transaction date. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 22:05 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Exercise / conversionCommon Stock | 75,000 | $3.43 | $257,250.00 |
DisclosureSEC source: 0001209191-18-037294 · doc4.xml · nonDerivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 20:07 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 50 | $3.40 | $170.00 |
DisclosureSEC source: 0001209191-18-019531 · doc4.xml · nonDerivative · entry 2 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,858 Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 20:07 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 2,015 | $3.40 | $6,840.93 |
DisclosureSEC source: 0001209191-18-019531 · doc4.xml · nonDerivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,808 Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 15:26 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 75,000 | $0.00 Strike: $4.19 | $0.00 |
DisclosureSEC source: 0001493152-18-001039 · form4.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 23, 2018 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 23, 2018 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| October 11, 2017 Filed Oct 13, 2017 21:34 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 6,250 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001662252-17-000209 · form4.xml · derivative · entry 4 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 6,250 shares Expires 2027-10-11 F1 · price: On October 11, 2017 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 25,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on October 11, 2017 of $2.95. The Option vests one-quarter of the total grant for each quarter of service over the twelve-month period commencing on the grant date. Read SEC document |
| October 11, 2017 Filed Oct 13, 2017 21:34 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 6,250 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001662252-17-000209 · form4.xml · derivative · entry 3 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires 2027-10-11 F1 · price: On October 11, 2017 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 25,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on October 11, 2017 of $2.95. The Option vests one-quarter of the total grant for each quarter of service over the twelve-month period commencing on the grant date. Read SEC document |
| October 11, 2017 Filed Oct 13, 2017 21:34 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 6,250 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001662252-17-000209 · form4.xml · derivative · entry 2 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2027-10-11 F1 · price: On October 11, 2017 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 25,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on October 11, 2017 of $2.95. The Option vests one-quarter of the total grant for each quarter of service over the twelve-month period commencing on the grant date. Read SEC document |
| October 11, 2017 Filed Oct 13, 2017 21:34 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 6,250 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001662252-17-000209 · form4.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2027-10-11 F1 · price: On October 11, 2017 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 25,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on October 11, 2017 of $2.95. The Option vests one-quarter of the total grant for each quarter of service over the twelve-month period commencing on the grant date. Read SEC document |
| September 15, 2017 Filed Sep 18, 2017 10:09 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 1,500 | $6.03 | $9,045.00 |
DisclosureSEC source: 0001209191-17-053087 · doc4.xml · nonDerivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,793 Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 17:48 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | Exercise / conversionRestricted Stock Units (RSUs) · Derivative | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-17-006770 · form4.xml · derivative · entry 2 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 12,500 shares Expires 2026-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. F2 · derivative.exercise_date: The restricted stock units vest 1/3 per year over 3 years, beginning on June 14, 2017, subject to continued service through each vesting date. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 17:48 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | Exercise / conversionCommon Shares, no par value per share | 12,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-17-006770 · form4.xml · nonDerivative · entry 1 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the right to receive, at settlement, one common share. This transaction represents the settlement of restricted stock units in common shares on their scheduled vesting date. Read SEC document |
| March 30, 2017 Filed Mar 31, 2017 20:10 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 12,500 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001493152-17-003308 · form4.xml · derivative · entry 1 Logal Adam · CIK 0001356197 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Shares · 12,500 shares Expires 2027-01-26 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 26, 2017 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated March 30, 2017 (the "Option Agreement"). The options vest and become exercisable in 48 equal monthly installments beginning on the first day of the month following the Grant Date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| March 14, 2017 Filed Mar 15, 2017 22:31 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | SaleCommon Stock | 112,975 | $8.07 | $911,674.36 |
DisclosureSEC source: 0001209191-17-020904 · doc4.xml · nonDerivative · entry 4 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,293 F3 · shares: All of the shares reported as disposed of in this Form 4 were sold to pay/satisfy federal and/or state tax withholding in connection with a stock option exercise on March 13, 2017. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.02 to $8.21, inclusive. The reporting person undertakes to provide to OPKO Health, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4. Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 22:31 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Exercise / conversionStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $2.36 | $0.00 |
DisclosureSEC source: 0001209191-17-020904 · doc4.xml · derivative · entry 6 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2017-04-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The options were granted on April 14, 2010 and vested in four equal installments beginning on April 14, 2011. Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 22:31 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Exercise / conversionStock Option (Right to Buy) · Derivative | 189,207 | $0.00 Strike: $0.56 | $0.00 |
DisclosureSEC source: 0001209191-17-020904 · doc4.xml · derivative · entry 5 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 189,207 shares Expires 2017-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option became exercisable in forty-eight (48) equal monthly installments until fully vested on March 15, 2011. Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 22:31 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Tax withholdingCommon Stock | 35,728 | $7.92 | $282,965.76 |
DisclosureSEC source: 0001209191-17-020904 · doc4.xml · nonDerivative · entry 3 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,268 F1 · shares: Represents number of shares withheld by the Company at the direction of the reporting person for the payment of exercise price. No shares of Common Stock were sold by the reporting person in connection with this transaction. The reporting person has retained the net number of shares issued upon the exercise of the option (228,479 shares). F2 · price: Closing market price of the Company's common stock on the transaction date. Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 22:31 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Exercise / conversionCommon Stock | 75,000 | $2.36 | $177,000.00 |
DisclosureSEC source: 0001209191-17-020904 · doc4.xml · nonDerivative · entry 2 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 13, 2017 Filed Mar 15, 2017 22:31 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | Exercise / conversionCommon Stock | 189,207 | $0.56 | $105,955.92 |
DisclosureSEC source: 0001209191-17-020904 · doc4.xml · nonDerivative · entry 1 Logal Adam · CIK 0001356197 · Sr. Vice President, CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.